Answers are grounded in this paper and cite their sources.
Previous studies have indicated that female animals are more resistant to carbon tetrachloride (CCl4)-induced liver fibrosis than male animals, and that estradiol (E2) treatment can inhibit CCl4-induced animal hepatic fibrosis. The underlying mechanism governing these phenomena, however, has not been fully elucidated. Here we reported the role of estrogen-induced miRNA-29 (miR-29) expression in CCl4-induced mouse liver injury. Hepatic miR-29 levels were differentially regulated in female and male mice during CCl4 treatment. Specifically, the levels of miR-29a and miR-29b expression were significantly decreased in the livers of male, but not female, mice following 4 weeks of CCl4 treatment. The down-regulation of miR-29a and miR-29b in male mouse livers correlated with the early development of liver fibrosis, as indicated by increased expressions of fibrotic markers in male mice relative to female mice. In addition, E2 was maintained at a higher level in female mice than in male mice. In contrast to TGF-β1 that decreased miR-29a/b expression in murine hepatoma IAR20 cells and normal hepatocytes, E2 enhanced the expression of miR-29a/b through suppression of the nuclear factor-κB (NF-κB) signal pathway, which negatively regulates miR-29 expression. Furthermore, both E2 treatment and intravenous injection of the recombinant adenovirus expressing miR-29a/b markedly increased the miR-29a/b level and attenuated the expression of fibrotic markers in mouse livers during CCl4 treatment, supporting the protective role of E2-induced miR-29 in CCl4-induced hepatic injury. In conclusion, our results collectively demonstrate that estrogen can inhibit CCl4-induced hepatic injury through the induction of hepatic miR-29. Previous studies have indicated that female animals are more resistant to carbon tetrachloride (CCl4)-induced liver fibrosis than male animals, and that estradiol (E2) treatment can inhibit CCl4-induced animal hepatic fibrosis. The underlying mechanism governing these phenomena, however, has not been fully elucidated. Here we reported the role of estrogen-induced miRNA-29 (miR-29) expression in CCl4-induced mouse liver injury. Hepatic miR-29 levels were differentially regulated in female and male mice during CCl4 treatment. Specifically, the levels of miR-29a and miR-29b expression were significantly decreased in the livers of male, but not female, mice following 4 weeks of CCl4 treatment. The down-regulation of miR-29a and miR-29b in male mouse livers correlated with the early development of liver fibrosis, as indicated by increased expressions of fibrotic markers in male mice relative to female mice. In addition, E2 was maintained at a higher level in female mice than in male mice. In contrast to TGF-β1 that decreased miR-29a/b expression in murine hepatoma IAR20 cells and normal hepatocytes, E2 enhanced the expression of miR-29a/b through suppression of the nuclear factor-κB (NF-κB) signal pathway, which negatively regulates miR-29 expression. Furthermore, both E2 treatment and intravenous injection of the recombinant adenovirus expressing miR-29a/b markedly increased the miR-29a/b level and attenuated the expression of fibrotic markers in mouse livers during CCl4 treatment, supporting the protective role of E2-induced miR-29 in CCl4-induced hepatic injury. In conclusion, our results collectively demonstrate that estrogen can inhibit CCl4-induced hepatic injury through the induction of hepatic miR-29.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: